Literature DB >> 31560200

Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.

Wenhu Zhan1, Hao-Chi Hsu2, Trevor Morgan3, Tierra Ouellette1, Kristin Burns-Huang1, Ryoma Hara4, Adrian G Wright3, Toshihiro Imaeda4, Rei Okamoto4, Kenjiro Sato4, Mayako Michino4, Manoj Ramjee3, Kazuyoshi Aso4, Peter T Meinke4, Michael Foley4, Carl F Nathan1, Huilin Li2, Gang Lin1.   

Abstract

Proteasomes of pathogenic microbes have become attractive targets for anti-infectives. Coevolving with its human host, n class="Species">Mycobacterium tuberculosis (Mtb) has developed mechanisms to resist host-imposed nitrosative and oxidative stresses. Genetic deletion or pharmacological inhibition of the Mtb proteasome (Mtb20S) renders nonreplicating Mtb susceptible to reactive nitrogen species in vitro and unable to survive in the lungs of mice, validating the Mtb proteasome as a promising target for anti-Mtb agents. Using a structure-guided and flow chemistry-enabled study of structure-activity relationships, we developed phenylimidazole-based peptidomimetics that are highly potent for Mtb20S. X-ray structures of selected compounds with Mtb20S shed light on their selectivity for mycobacterial over human proteasomes.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31560200      PMCID: PMC7091493          DOI: 10.1021/acs.jmedchem.9b01187

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

1.  Continuous-flow injection microfluidic thrombin assays: The effect of binding kinetics on observed enzyme inhibition.

Authors:  Manoj K Ramjee; Sital Patel
Journal:  Anal Biochem       Date:  2017-04-27       Impact factor: 3.365

2.  Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform.

Authors:  Bimbisar Desai; Karen Dixon; Elizabeth Farrant; Qixing Feng; Karl R Gibson; Willem P van Hoorn; James Mills; Trevor Morgan; David M Parry; Manoj K Ramjee; Christopher N Selway; Gary J Tarver; Gavin Whitlock; Adrian G Wright
Journal:  J Med Chem       Date:  2013-03-25       Impact factor: 7.446

3.  The Proteasome as a Drug Target in the Metazoan Pathogen, Schistosoma mansoni.

Authors:  Betsaida Bibo-Verdugo; Steven C Wang; Jehad Almaliti; Anh P Ta; Zhenze Jiang; Derek A Wong; Christopher B Lietz; Brian M Suzuki; Nelly El-Sakkary; Vivian Hook; Guy S Salvesen; William H Gerwick; Conor R Caffrey; Anthony J O'Donoghue
Journal:  ACS Infect Dis       Date:  2019-08-12       Impact factor: 5.084

4.  Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.

Authors:  Hao Fan; Nicholas G Angelo; J David Warren; Carl F Nathan; Gang Lin
Journal:  ACS Med Chem Lett       Date:  2014-02-03       Impact factor: 4.345

Review 5.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

6.  Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.

Authors:  Gang Lin; Christopher Tsu; Lawrence Dick; Xi K Zhou; Carl Nathan
Journal:  J Biol Chem       Date:  2008-10-01       Impact factor: 5.157

7.  The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide.

Authors:  K Heran Darwin; Sabine Ehrt; José-Carlos Gutierrez-Ramos; Nadine Weich; Carl F Nathan
Journal:  Science       Date:  2003-12-12       Impact factor: 47.728

8.  Ubiquitin-like protein involved in the proteasome pathway of Mycobacterium tuberculosis.

Authors:  Michael J Pearce; Julian Mintseris; Jessica Ferreyra; Steven P Gygi; K Heran Darwin
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

9.  In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice.

Authors:  Sheetal Gandotra; Dirk Schnappinger; Mercedes Monteleone; Wolfgang Hillen; Sabine Ehrt
Journal:  Nat Med       Date:  2007-12-02       Impact factor: 53.440

10.  Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.

Authors:  Shilpi Khare; Advait S Nagle; Agnes Biggart; Yin H Lai; Fang Liang; Lauren C Davis; S Whitney Barnes; Casey J N Mathison; Elmarie Myburgh; Mu-Yun Gao; J Robert Gillespie; Xianzhong Liu; Jocelyn L Tan; Monique Stinson; Ianne C Rivera; Jaime Ballard; Vince Yeh; Todd Groessl; Glenn Federe; Hazel X Y Koh; John D Venable; Badry Bursulaya; Michael Shapiro; Pranab K Mishra; Glen Spraggon; Ansgar Brock; Jeremy C Mottram; Frederick S Buckner; Srinivasa P S Rao; Ben G Wen; John R Walker; Tove Tuntland; Valentina Molteni; Richard J Glynne; Frantisek Supek
Journal:  Nature       Date:  2016-08-08       Impact factor: 49.962

View more
  7 in total

1.  Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.

Authors:  Hao Zhang; Hao-Chi Hsu; Shoshanna C Kahne; Ryoma Hara; Wenhu Zhan; Xiuju Jiang; Kristin Burns-Huang; Tierra Ouellette; Toshihiro Imaeda; Rei Okamoto; Masanori Kawasaki; Mayako Michino; Tzu-Tshin Wong; Akinori Toita; Takafumi Yukawa; Francesca Moraca; Jeremie Vendome; Priya Saha; Kenjiro Sato; Kazuyoshi Aso; John Ginn; Peter T Meinke; Michael Foley; Carl F Nathan; K Heran Darwin; Huilin Li; Gang Lin
Journal:  J Med Chem       Date:  2021-05-05       Impact factor: 7.446

Review 2.  Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.

Authors:  David J Sherman; Jing Li
Journal:  Molecules       Date:  2020-02-05       Impact factor: 4.411

Review 3.  Microbial proteasomes as drug targets.

Authors:  Hao Zhang; Gang Lin
Journal:  PLoS Pathog       Date:  2021-12-09       Impact factor: 6.823

Review 4.  Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes.

Authors:  James J Ignatz-Hoover; Elena V Murphy; James J Driscoll
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

5.  Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome.

Authors:  Kaja Rožman; Evan M Alexander; Eva Ogorevc; Krištof Bozovičar; Izidor Sosič; Courtney C Aldrich; Stanislav Gobec
Journal:  Molecules       Date:  2020-03-12       Impact factor: 4.411

Review 6.  Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.

Authors:  Yu Cao; Huajian Zhu; Ruoyu He; Limin Kong; Jiaan Shao; Rangxiao Zhuang; Jianjun Xi; Jiankang Zhang
Journal:  Drug Des Devel Ther       Date:  2020-10-19       Impact factor: 4.162

Review 7.  Control of Toxin-Antitoxin Systems by Proteases in Mycobacterium Tuberculosis.

Authors:  Patricia Bordes; Pierre Genevaux
Journal:  Front Mol Biosci       Date:  2021-05-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.